



Prof. Roger von Moos

Contact

Prof. Roger von Moos
Switzerland

Publications (60)

de Joode K, Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard C, Läubli H, Michielin O, von Moos R, Jörgler M, Levesque M, Aepli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex S, Mathijssen R, Metaxas Y. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. *J Immunother* 2024; 47:190-194.

Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, Chiquet S, Schneider M, Ribl K, Maranta A, Bastian S, von Moos R, Jörgler M, Früh M, Swiss Group for Clinical Cancer Research (SAKK). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. *Eur J Cancer* 2024; 200:113600.

Jörgler M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. *Invest New Drugs* 2023; 41:267-275.

Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörgler M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). *Br J Clin Pharmacol* 2022; 88:5336-5347.

Jörgler M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Stoffel S, Lupatsch J, Schwenkglens M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillessen S, Cathomas R, Thürlimann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study. *Swiss Med Wkly* 2021; 151:w20464.

Ribl K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlimann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). *BMC cancer* 2021; 21:182.

Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. *Clin Cancer Res* 2020; 27:179-188.

Mark M, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Ribl K, Thürlimann B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). *J Bone Oncol* 2019; 21:100273.

Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. *BMC cancer* 2019; 19:902.

Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. *Invest New Drugs* 2019

Jörger M, Gueller U, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. *J Gastrointest Oncol* 2019; 10:373-378.

Mark M, Strebel R, Manetsch G, Pollak M, von Moos R, Gillesen Sommer S, Rothermundt C, Winterhalder R, Mey U, Klingbiel D, Cathomas R. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. *Clin Genitourin Cancer* 2019

Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. *J Geriatr Oncol* 2018; 10:304-310.

Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrusch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. *J Thorac Oncol* 2018

Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). *Eur J Cancer* 2018; 96:6-16.

von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). *Eur J Cancer* 2017; 89:82-89.

Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. *Endocr Connect* 2017; 6:549-556.

Pestalozzi B, Novak U, Nussbaum C, Seifert B, Bigler M, Bize V, Vilei S, Rageth C, Aebi S, Borner M, Buser K, Tausch C, Dedes K, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). *BMC cancer* 2017; 17:265.

Borgquist S, Regan M, Gelber R, Price K, Rabaglio M, Goldhirsch A, Coates A, Smith I, von Moos R, Ejlertsen B, Debled M, Láng I, Colleoni M, Garber J, Ahern T, Giobbie-Hurder A, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. *J Clin Oncol* 2017; 35:1179-1188.

Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. *Br J Haematol* 2016

Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. *BMC cancer* 2016; 16:780.

Dummer R, Guckenberger M, Najafi Y, von Moos R, Mihic-Probst D, Michielin O, Braun R, Lindenblatt N, Hunger R, Siano M, Arnold A. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. *Swiss Med Wkly* 2016; 146:w14279.

Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörgler M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). *Haematologica* 2015; 101:346-55.

Peters S, von Moos R, Thürlimann B. [Is prescription of a therapy costing 150,000 CHF reasonable?]. *Rev Med Suisse* 2015; 11:1967-72.

Cathomas R, Rothermundt C, Bode B, Fuchs B, von Moos R, Schwitler M. RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?. *Oncology* 2014; 88:257-260.

Templeton A, Ruhstaller T, Thürlimann B, Zaman K, von Moos R, Rochlitz C, Winterhalder R, von Rohr L, Müller A, Winkler A, Borner M, Dietrich D, Beyeler M, Hsu Schmitz S, Sun H, Surber C, Ribi K, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). *Breast* 2014; 23:244-9.

Leitner C, von Moos R, Früh M, Mark M, Cathomas R. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. *Cancer Treatment Communications* 2014; 2:4-7.

Anghel R, Bachmann A, Beksac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Láng I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. *Wien Klin Wochenschr* 2013; 125:439-47.

Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. *PloS one* 2013; 8:e53745.

Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). *Clin Cancer Res* 2012; 18:6049-57.

Schoenewolf N, von Moos R, Schraml P, Gillessen Sommer S, Ochsenbein A, Simcock M, Moch H, Mihic-Probst D, Dummer R, Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. *Case Rep Oncol* 2012; 5:280-9.

Schraml P, Moch H, Schläppi M, Seifert B, Michielin O, Dummer R, Ochsenbein A, Simcock M, Mihic-Probst D, von Teichman A, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. *Oncol Rep* 2012

Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribí K, Zouhair A, von Moos R, Schläppi M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). *Eur J Cancer* 2011; 48:377-84.

Huober J, Widmer I, von Rohr L, Müller A, von Moos R, Güth U, Aebi S, Rochlitz C, Baumann M, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. *Oncology* 2011; 81:160-166.

Hundsberger T, Tettenborn B, von Moos R, Fournier J, Anliker M, Gähler A, Fretz C, Kleger G, Cogliatti S, Driessen C. Intravascular lymphoma mimicking cerebral stroke: report of two cases. *Case Rep Neurol* 2011; 3:278-283.

Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). *J Clin Oncol* 2011; 29:626-31.

Heinzerling L, Anliker M, Müller J, Schläppi M, von Moos R. Sarcoidosis induced by interferon- α in melanoma patients: incidence, clinical manifestations, and management strategies. *J Immunother* 2010; 33:834-9.

von Moos R, Caspar C, Steiner R, Angst R, Inauen R, Schmieding K, Thürlimann B. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. *Onkologie* 2010; 33:447-50.

Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribí K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). *Onkologie* 2010; 33:222-8.

von Moos R, Lanz D, Simcock M, Köberle D, Cathomas R, Uhlmann C, Widmer L, Ruhstaller T, Roth A, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). *Onkologie* 2010; 33:295-9.

Schläppi M, Anliker M, Heinzerling L, von Moos R. Malignes Melanom - Inzidenz, Früherkennung und therapeutische Optionen. *Facharzt* 2010; 2:4-7.

Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribí K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer. *Onkologie* 2010; 33:222-228.

Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). *Onkologie* 2009; 32:724-30.

von Moos R, Goldinger S, Michielin O, Schuller J, Gillessen Sommer S, Schlaeppi M, Cathomas R, Ochsenbein A, Seifert B, Dummer R (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). Presented at: ECCO / ESMO, Berlin

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009

Ribi K, Pestalozzi B, Lombriser N, Borner M, von Moos R, Moosmann P, Hess V, Roth A, Honegger H, Schuller J, Köberle D, Ruhstaller T. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116.

Ruhstaller T, Böhme C, Hess D, Hoefliger M, Mueller U, Köberle D, Spaeti B, Glaus A, Ribi K, Rufibach K, von Moos R, Thürlimann B. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 2009; 76:142-8.

Grimm B, Padberg B, Ruhstaller T, Fleisch F, von Moos R. Fatal herpes simplex virus hepatitis in a patient with esophageal cancer under radiochemotherapy. Onkologie 2008; 31:620-2.

von Moos R, Strasser F, Gillessen Sommer S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2008; 16:1105-15.

von Moos R, Lademann J, Lacouture M, Dummer R, Lorusso D, Scotte F, Sehoul J, Harrold K, Rayson D, Apro M, Thürlimann B, Hauschild A. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. EJO 2008; 44:781-90.

Schlaeppi M, Anliker M, von Moos R. Malignes Melanom. TMJ 2008; 2:17-19.

Ruhstaller T, Thürlimann B, Köberle D, von Moos R. Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?. JCO 2007; 25:4025-6; author reply 4026-7.

Salzberg M, Thürlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann A, Ruhstaller T, Stopatschinskaja S, von Moos R. Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology 2007; 72:147-51.

Waeckerle-Men Y, Groettrup M, Ludwig B, Cerny T, Ackermann D, Schmid H, Böhme C, von Moos R, Fopp M, Uetz-von Allmen E, Gillessen Sommer S. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer immunology, immunotherapy : CII 2006; 55:1524-33.

Schlaeppi M, Korte W, von Moos R, Cerny T, Gillessen Sommer S. Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma. Onkologie 2006; 29:531-3.

von Moos R, Ruhstaller T, Fretz C. CASE 3. Red eye in Sjogren's syndrome due to underlying mucosa-associated lymphoid tissue lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:1011-3.

Waeckerle-Men Y, Allmen E, von Moos R, Classon B, Scandella E, Schmid H, Ludewig B, Groettrup M, Gillessen Sommer S. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. *The Prostate* 2005; 64:323-31.

Salzberg M, Thürlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, Senn H. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. *Oncology* 2005; 68:293-8.

von Moos R, Stolz R, Cerny T, Gillessen Sommer S. Thalidomide: from tragedy to promise. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2003; 133:77-87.

Projects (1)

Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK 19/05)

Fundamental Research - Apr 1, 2012 - Sep 1, 2013

Completed

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch